Long term efficacy and assessment of tumor response of transarterial chemoembolization in neuroendocrine liver metastases: A 15‐year monocentric experience

Caroline Touloupas, Matthieu Faron, Julien Hadoux, Frédéric Deschamps, Charles Roux, Maxime Ronot, Steven Yevich, Julien Joskin, Maximiliano Gelli, Rémy Barbé, Livia Lamartina, Hubert Tissot, Jean Yves Scoazec, David Malka, Michel Ducreux, Eric Baudin, Thierry de Baère, Lambros Tselikas

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    23 Citations (Scopus)

    Résumé

    Background: transarterial chemoembolization (TACE) is an established treatment for neu-roendocrine tumor (NET) liver metastases. The aim was to evaluate the long‐term treatment efficacy of TACE for NET liver metastases, and correlate imaging response with survival. Methods: this IRB-approved, single‐center, retrospective study evaluated all TACE procedures performed for NET liver metastases from 2003–2017 for imaging tumor response (RECIST and mRECIST), time to liver progression (TTLP), time to untreatable progression with TACE (TTUP), and overall survival (OS). Patient, tumor, and treatment characteristics were analyzed as prognostic factors. Survival curves according to the Kaplan–Meier method were compared by Log‐rank test. Tumor responses accord‐ ing to RECIST and mRECIST were correlated with OS. Results: 555 TACE procedures were performed in 202 NET patients (38% grade 1, 60% grade 2) with primary tumors originating from pan-creas, small bowel, and lung (39, 26, and 22% respectively). Median follow‐up was 8.2 years (90–139 months). Median TTLP and TTUP were 19.3 months (95%CI 16.3–22.3) and 26.2 months (95%CI 22.3– 33.1), respectively. Median OS was 5.3 years (95%CI 4.2–6.7), and was higher among mRECIST re-sponders (80.5 months; 95%CI 64.6–89.8) than in non‐responders (39.6 months; 95%CI = 32.8–60.2; p < 0.001). In multivariable analysis, age, tumor grade and liver involvement predicted worse OS, whereas administration of somatostatin analogs correlated with improved OS. Conclusion: TACE for NET liver metastases provides objective response and sustained local disease control rates. RE‐ CIST and mRECIST responses correlate with OS.

    langue originaleAnglais
    Numéro d'article5366
    journalCancers
    Volume13
    Numéro de publication21
    Les DOIs
    étatPublié - 1 nov. 2021

    Contient cette citation